Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta ® and Nucynta ® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025, to July 3, 2026. FDA's grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER. “We are pleased with FDA's grant of pediatric exclusivity for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium's Chief Medical Officer. “This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve.” Nucynta i
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years [Yahoo! Finance]Yahoo! Finance
- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta FranchiseGlobeNewswire
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $44.00 price target on the stock, up previously from $41.00.MarketBeat
- Collegium to Participate in Jefferies Global Healthcare ConferenceGlobeNewswire
- Collegium Announces $35 Million Accelerated Share Repurchase ProgramGlobeNewswire
COLL
Earnings
- 5/9/24 - Beat
COLL
Sec Filings
- 6/13/24 - Form 8-K
- 6/5/24 - Form 144
- 6/5/24 - Form 4
- COLL's page on the SEC website